Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Mark S. Duxon"'
Autor:
Mark S. Duxon, Peter J. Atkinson, Tracey E. Shaw, David R. Thomas, Kevin M. Thewlis, Michael S. Hadley, Beverley Hammond, Geoffrey Stemp, Gary W. Price, Claire M. Scott, Vong Antonio Kuok Keong, Jeannette M. Watson, Steven Mark Bromidge, Christopher N. Johnson, Graham J. Riley, Derek N. Middlemiss, Harshad Kantilal Rami, Stephanie E. North, Laramie Mary Gaster, Kathryn R. Starr, Mervyn Thompson
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:737-741
Starting from a high throughput screening hit, a series of 3,4-dihydro-2H-benzoxazinones has been identified with both high affinity for the 5-HT(1A) receptor and potent 5-HT reuptake inhibitory activity. The 5-(2-methyl)quinolinyloxy derivative comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc0251a65c1ec7fac2128405b3379b6c
https://doi.org/10.1016/j.bmcl.2004.11.030
https://doi.org/10.1016/j.bmcl.2004.11.030
Autor:
Colin A. Campbell, A. Lawman, Tania O. Stean, Andrew Billinton, Neil Upton, Leann P. Quinn, Sarah Collier, Elaine A. Irving, Robert I. Grundy, Mark S. Duxon, Andrew A. Parsons
Publikováno v:
Brain Research. 1031:118-124
Following stroke, patients suffer a wide range of disabilities including motor impairment, anxiety and depression. However, to date, characterisation of rodent stroke models has concentrated mainly on the investigation of motor deficits. The aim of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01eb74049ea8bad7806dad0bb15e46cc
https://doi.org/10.1016/j.brainres.2004.10.036
https://doi.org/10.1016/j.brainres.2004.10.036
Publikováno v:
European Journal of Pharmacology. 493:95-98
The vasoactive peptide urotensin-II and its receptor, GPR14 (now known as UT receptor), are localised in the mammalian central nervous system. Accordingly, various centrally mediated effects of urotensin-II on behaviour, neuroendocrine hormones and n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a081b94ce4ba4cc2e30ad209bbcd40d8
https://doi.org/10.1016/j.ejphar.2004.04.009
https://doi.org/10.1016/j.ejphar.2004.04.009
Autor:
Brenda K. Trail, Sharon C Stratton, Leann P. Quinn, Andrew Billinton, Mark S. Duxon, Tania O. Stean, Neil Upton
Publikováno v:
Journal of Neuroscience Methods. 130:83-92
A newly developed apparatus for automated behavioural analysis, Laboratory Animal Behaviour Observation, Registration and Analysis System (LABORAS), has been further validated with respect to the ability of the system to detect the pharmacodynamic ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2493c45a984028d62202958d24a43128
https://doi.org/10.1016/s0165-0270(03)00227-9
https://doi.org/10.1016/s0165-0270(03)00227-9
Publikováno v:
Psychopharmacology. 161:314-323
Rationale and objectives. The unstable elevated exposed plus maze (UEEPM) has been proposed as a novel model of anxiety which elicits unconditioned escape-related behaviour in rats thought to mimic the persistent "fight/flight" state exhibited by pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c601c703f475cc11485d41833f94500
https://doi.org/10.1007/s00213-002-1029-y
https://doi.org/10.1007/s00213-002-1029-y
Publikováno v:
Pharmacology Biochemistry and Behavior. 71:599-605
5-HT(2) receptor antagonists promote slow wave sleep (SWS) in humans and rats, conversely 5-HT(2) agonists inhibit SWS in rats. These alterations are thought to be predominantly mediated via the 5-HT(2C) receptor subtype. It is evident that 5-HT(2) r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdd266a360e44522fd39b38d1a217cf5
https://doi.org/10.1016/s0091-3057(01)00702-x
https://doi.org/10.1016/s0091-3057(01)00702-x
Autor:
Douglas R Smith, Warren D. Hirst, Derek C. Rogers, Neil Upton, Mark S. Duxon, Nigel Deeks, Sarah Bartlett, Graham J. Riley, Tania O. Stean, David R. Thomas, Gary W. Price, Steven Mark Bromidge, Halina T Serafinowska
Publikováno v:
Pharmacology Biochemistry and Behavior. 71:645-654
N -(2,5-Dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134) potently inhibited [ 125 I]SB-258585 and [ 3 H]LSD binding in a HeLa cell line expressing human 5-HT 6 receptors (p K i =8.6 and 8.54, respectively). Furthermore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2141213f563d15a02070c4ab6b5b8a4
https://doi.org/10.1016/s0091-3057(01)00742-0
https://doi.org/10.1016/s0091-3057(01)00742-0
Autor:
Neil Upton, Stephen J. Brough, Graham J. Riley, Kathryn R. Starr, Mark S. Duxon, Darren Smart, Jeff C. Jerman, Jennifer Stretton, Declan N.C. Jones, Vicky Holland, Roderick A. Porter, Amanda Johns, Wai Chan
Publikováno v:
Psychopharmacology. 153:203-209
Rationale: Orexins A and B have recently been discovered and shown to be derived from prepro-orexin, primarily expressed in the rat hypothalamus. Orexin-A has been ascribed a number of in vivo functions in the rat after intracerebroventricular (ICV)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fc21b93e05c58fb17a27f8b1e7989cf
https://doi.org/10.1007/s002130000550
https://doi.org/10.1007/s002130000550
Publikováno v:
Neuroscience Letters. 341:256-258
The neuropeptide orexin-A modulates the sleep–wake cycle such that central administration to rats increases arousal, reduces slow-wave-sleep (SWS) and paradoxical sleep (PS) and delays PS onset. The contribution of orexin-1 and -2 receptor (OXR) ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a73d2e1847c136f38cf7762f100e3fa
https://doi.org/10.1016/s0304-3940(03)00066-1
https://doi.org/10.1016/s0304-3940(03)00066-1
Autor:
Gary W. Price, Jeannette M. Watson, Kathryn R. Starr, Sergio Melotto, Peter J. Atkinson, Mark S. Duxon, Roberto Arban, Neil Upton, Jim J. Hagan, Lee A. Dawson
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 32(10)
Preclinically, the combination of an SSRI and 5-HT autoreceptor antagonist has been shown to reduce the time to onset of anxiolytic activity compared to an SSRI alone. In accordance with this, clinical data suggest the coadministration of an SSRI and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9312d40a1255723319db16ddfd2d443
https://pubmed.ncbi.nlm.nih.gov/17356576
https://pubmed.ncbi.nlm.nih.gov/17356576